"Topotecan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Concept/Terms
Topotecan- Topotecan
- 9-Dimethylaminomethyl-10-hydroxycamptothecin
- 9 Dimethylaminomethyl 10 hydroxycamptothecin
- Hycamtamine
Topotecan Hydrochloride- Topotecan Hydrochloride
- Hydrochloride, Topotecan
- Topotecan Monohydrochloride, (S)-Isomer
- Nogitecan Hydrochloride
- Hydrochloride, Nogitecan
SK&F-104864-A- SK&F-104864-A
- SK&F 104864 A
- SK&F104864A
- SKF-104864-A
- SKF 104864 A
- SKF104864A
Hycamtin- Hycamtin
- SmithKline Beecham Brand of Topotecan Hydrochloride
Below are MeSH descriptors whose meaning is more general than "Topotecan".
Below are MeSH descriptors whose meaning is more specific than "Topotecan".
This graph shows the total number of publications written about "Topotecan" by people in Harvard Catalyst Profiles by year, and whether "Topotecan" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 3 | 3 |
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 3 | 4 |
| 2000 | 1 | 3 | 4 |
| 2001 | 3 | 3 | 6 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 2 | 3 |
| 2004 | 3 | 5 | 8 |
| 2005 | 2 | 3 | 5 |
| 2006 | 4 | 1 | 5 |
| 2007 | 3 | 0 | 3 |
| 2008 | 1 | 4 | 5 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 3 | 5 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 4 | 4 |
| 2017 | 2 | 3 | 5 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
Below are the most recent publications written about "Topotecan" by people in Profiles.
-
Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors. Leukemia. 2020 11; 34(11):2992-3006.
-
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601.
-
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 03 01; 26(5):1009-1016.
-
Tandem high-dose chemotherapy with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin regimens for pediatric high-risk brain tumors. Int J Clin Oncol. 2019 Dec; 24(12):1515-1525.
-
ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncol. 2019 Jan; 15(3):231-239.
-
Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. Thorac Cancer. 2018 12; 9(12):1699-1706.
-
Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo. Cancer Lett. 2018 06 28; 424:19-29.
-
Ataxia Telangiectasia-Mutated and Rad3-Related Inhibition and Topoisomerase I Trapping Create a Synthetic Lethality in Cancer Cells. J Clin Oncol. 2018 06 01; 36(16):1628-1630.
-
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro Oncol. 2017 Nov 29; 19(12):1607-1617.
-
Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming. Sci Rep. 2017 08 07; 7(1):7425.